三年估值狂飙240倍，“中医第一股”带疑冲刺IPO

Core Viewpoint - 甘之草科技股份有限公司 is positioning itself as a leading player in the online traditional Chinese medicine market, aiming for an IPO on the Hong Kong Stock Exchange, with significant growth in market share and valuation over a short period [1][5]. Financial Performance - In 2023, the company's revenue increased from 603 million RMB to 690 million RMB, achieving profits of 1.88 million RMB and 10.16 million RMB in consecutive years, alongside healthy cash inflows from operating activities [5]. - However, in 2025, despite a revenue of 554 million RMB and a gross profit of 150 million RMB in the first three quarters, the company reported a loss of 1.235 million RMB, indicating a reversal in profitability [5]. - The cash flow from operating activities turned negative, with a net outflow of 640,000 RMB, suggesting challenges in the company's core business operations [5]. Valuation Growth - The company's valuation skyrocketed from 6.775 million RMB to 1.639 billion RMB, a more than 240-fold increase within three years, driven by aggressive institutional investments prior to the IPO [5][10]. - The first significant institutional investment occurred in early 2024, with a valuation increase of over 118 times following the entry of professional investors [7]. - By January 2026, the latest financing round pushed the valuation to a historic high of 1.639 billion RMB, with multiple investment firms participating [10][11]. Capital Structure Changes - The ownership structure began diversifying in 2023, with external capital entering the company, marking a shift from founder-led to a more varied shareholder base [6]. - The capital influx in 2025 further accelerated the valuation increase, with significant investments leading to a valuation rise of 54% within six months [9]. Investment Strategy - The pattern of "pre-IPO rush investments" is evident, where institutional investors aim to capitalize on the company's valuation before its public offering, creating a clear chain of value enhancement [12]. - The focus on capital accumulation and resource enhancement through these investments is crucial for the company's future IPO prospects [12].